Austin, Texas – Colossal Biosciences has announced the acquisition of Viagen (https://viagenpets.com/). According to the company announcement Colossal Biosciences is a de-extinction company that utilizes CRISPR technology for species restoration and the protection of critically endangered species. The company aims to restore critical ecosystems to support life on Earth while also addressing future economic and biological necessities through advanced science. A notable achievement for the company is its acquisition of Viagen Pets and Equine, the global leader in animal cloning and genetic preservation. This acquisition positions Colossal as a key player in de-extinction by integrating Viagen’s proprietary technologies for cloning, cryopreservation, and reanimation. Through this strategic move, Colossal is enhancing its technology platform to advance its mission of global de-extinction and species preservation.

To learn more about Colossal Biosciences, visit https://colossal.com/
Company LinkedIn Page: https://www.linkedin.com/company/colossal/

Company Contact:

Colossal Biosciences
1401 Lavaca Street Suite 155
Austin, TX 78701
815-609-7600

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.